About Us – Anpac Bio

Working to detect cancer before tumors start.

Most people can survive cancer if it is caught early, so we have made that our goal.

Anpac Bio, founded in 2010, is drawing on diverse & extensive expertise. Since 2015 we have generated revenues providing cancer screening services in China with one of the largest global blood databases of over 140,000 samples.

A cross disciplinary team.

Cancer Research & Detection

Chemistry & Bio-chemistry

Nano-technology & Physics

Surface & Material Science

Engineering & Manufacturing

Who we are

Our world class leaders started with the question, “What if we could detect cancer before tumors start?”

Co-Founders, Dr. Chris Yu and Dr. Herbert Yu have brought together a multi-national team of medical, biomedical and nanotechnology scientists, and engineering experts. Their cross-disciplinary approach combines numerous fields of science, medicine and engineering to achieve our innovative, patented early cancer screening and detection technology.

Meet Our Leadership Team

210 patent applications filed globally with 121 patent applications granted.*

Our patented Cancer Differentiation Analysis (CDA) technology requires only a standard blood sample from a tested individual to conduct an early cancer screening and detection test, with no side effects in patients.

How CDA Technology Works

*As of September 30, 2019

“game changing”

CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article

Quick Links

Contact Information

Anpac Technology USA (Anpac Bio)
2260 Clove Dr. Suite 127
San Jose, CA 95128

Email: [email protected]

Phone Number: +1 (267) 810-6776

Anpac Bio-Medical Science Co., Ltd.

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.